Tempus AI, Inc. (NASDAQ:TEM) Director Sells 990 Shares

by · The Cerbat Gem

Tempus AI, Inc. (NASDAQ:TEM – Get Free Report) Director David R. Epstein sold 990 shares of the company’s stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $46.83, for a total value of $46,361.70. Following the sale, the director now owns 26,284 shares of the company’s stock, valued at approximately $1,230,879.72. This trade represents a 3.63 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Tempus AI Trading Up 5.0 %

Tempus AI stock traded up $2.29 during trading hours on Wednesday, hitting $48.03. The stock had a trading volume of 11,624,616 shares, compared to its average volume of 5,018,028. Tempus AI, Inc. has a fifty-two week low of $22.89 and a fifty-two week high of $91.45. The company has a 50-day moving average of $55.86 and a two-hundred day moving average of $51.48. The company has a current ratio of 2.69, a quick ratio of 2.55 and a debt-to-equity ratio of 8.17.

Institutional Trading of Tempus AI

Several institutional investors have recently made changes to their positions in the business. ARK Investment Management LLC lifted its stake in Tempus AI by 132.1% during the fourth quarter. ARK Investment Management LLC now owns 5,519,644 shares of the company’s stock worth $186,343,000 after purchasing an additional 3,141,487 shares during the period. NEA Management Company LLC grew its holdings in shares of Tempus AI by 17.8% in the 3rd quarter. NEA Management Company LLC now owns 5,385,979 shares of the company’s stock worth $304,846,000 after purchasing an additional 813,169 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. increased its holdings in shares of Tempus AI by 166.0% during the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 3,239,093 shares of the company’s stock worth $109,352,000 after buying an additional 2,021,394 shares in the last quarter. Nikko Asset Management Americas Inc. increased its holdings in Tempus AI by 166.0% during the 4th quarter. Nikko Asset Management Americas Inc. now owns 3,239,093 shares of the company’s stock valued at $109,352,000 after purchasing an additional 2,021,394 shares in the last quarter. Finally, Franklin Resources Inc. increased its stake in shares of Tempus AI by 240.5% in the fourth quarter. Franklin Resources Inc. now owns 2,762,173 shares of the company’s stock valued at $93,251,000 after buying an additional 1,950,862 shares in the last quarter. 24.22% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on TEM. Piper Sandler decreased their target price on Tempus AI from $70.00 to $55.00 and set a “neutral” rating for the company in a research report on Tuesday, March 4th. William Blair reiterated a “market perform” rating on shares of Tempus AI in a research note on Tuesday, February 25th. Guggenheim reiterated a “buy” rating on shares of Tempus AI in a report on Tuesday, February 25th. Morgan Stanley upped their price target on shares of Tempus AI from $50.00 to $60.00 and gave the company an “overweight” rating in a report on Thursday, March 6th. Finally, JPMorgan Chase & Co. lowered Tempus AI from an “overweight” rating to a “neutral” rating and lifted their price objective for the stock from $50.00 to $55.00 in a research note on Tuesday, February 25th. Six investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat.com, Tempus AI currently has an average rating of “Moderate Buy” and a consensus price target of $61.18.

Check Out Our Latest Analysis on Tempus AI

About Tempus AI

(Get Free Report)

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.

Featured Articles